JP2025515474A5 - - Google Patents
Info
- Publication number
- JP2025515474A5 JP2025515474A5 JP2024563280A JP2024563280A JP2025515474A5 JP 2025515474 A5 JP2025515474 A5 JP 2025515474A5 JP 2024563280 A JP2024563280 A JP 2024563280A JP 2024563280 A JP2024563280 A JP 2024563280A JP 2025515474 A5 JP2025515474 A5 JP 2025515474A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- flocculant
- oil
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263336743P | 2022-04-29 | 2022-04-29 | |
| US63/336,743 | 2022-04-29 | ||
| PCT/US2023/066395 WO2023212721A1 (en) | 2022-04-29 | 2023-04-28 | Injectable suspensions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515474A JP2025515474A (ja) | 2025-05-15 |
| JP2025515474A5 true JP2025515474A5 (enExample) | 2026-05-07 |
Family
ID=86558725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024563280A Pending JP2025515474A (ja) | 2022-04-29 | 2023-04-28 | 注射可能な懸濁液 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240270864A1 (enExample) |
| EP (1) | EP4514324A1 (enExample) |
| JP (1) | JP2025515474A (enExample) |
| KR (1) | KR20250029029A (enExample) |
| CN (1) | CN119403542A (enExample) |
| AU (1) | AU2023260936A1 (enExample) |
| CA (1) | CA3248272A1 (enExample) |
| MX (1) | MX2024012785A (enExample) |
| WO (1) | WO2023212721A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017364077A1 (en) | 2016-11-22 | 2019-06-20 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| WO2019023392A1 (en) | 2017-07-25 | 2019-01-31 | Elektrofi, Inc. | FORMATION OF PARTICLES COMPRISING AGENTS |
| US12115262B2 (en) | 2018-05-24 | 2024-10-15 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| CN113365609A (zh) | 2019-01-31 | 2021-09-07 | 伊勒卓菲公司 | 颗粒形成和形态 |
| WO2021050953A1 (en) | 2019-09-13 | 2021-03-18 | Elektrofi, Inc. | Compositions and methods for the delivery of therapeutic biologics for treatment of disease |
| US12377050B2 (en) | 2020-04-17 | 2025-08-05 | Elektrofi, Inc. | Methods of forming particles by continuous droplet formation and dehydration |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| WO1999038504A1 (en) | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| AU2017364077A1 (en) | 2016-11-22 | 2019-06-20 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| WO2019023392A1 (en) | 2017-07-25 | 2019-01-31 | Elektrofi, Inc. | FORMATION OF PARTICLES COMPRISING AGENTS |
| US12115262B2 (en) | 2018-05-24 | 2024-10-15 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| CN113365609A (zh) | 2019-01-31 | 2021-09-07 | 伊勒卓菲公司 | 颗粒形成和形态 |
| WO2021050953A1 (en) | 2019-09-13 | 2021-03-18 | Elektrofi, Inc. | Compositions and methods for the delivery of therapeutic biologics for treatment of disease |
| US20230094393A1 (en) | 2020-02-07 | 2023-03-30 | Elektrofi, Inc. | Peptide particles and methods of formation |
| WO2021168271A1 (en) | 2020-02-19 | 2021-08-26 | Elektrofi, Inc. | Droplet formation and particle morphology |
| US12377050B2 (en) | 2020-04-17 | 2025-08-05 | Elektrofi, Inc. | Methods of forming particles by continuous droplet formation and dehydration |
| WO2022256840A2 (en) | 2021-06-04 | 2022-12-08 | Elektrofi, Inc. | Methods for screening particle formulations comprising proteins |
-
2023
- 2023-04-28 AU AU2023260936A patent/AU2023260936A1/en active Pending
- 2023-04-28 EP EP23726263.9A patent/EP4514324A1/en active Pending
- 2023-04-28 CA CA3248272A patent/CA3248272A1/en active Pending
- 2023-04-28 KR KR1020247039410A patent/KR20250029029A/ko active Pending
- 2023-04-28 WO PCT/US2023/066395 patent/WO2023212721A1/en not_active Ceased
- 2023-04-28 CN CN202380043717.1A patent/CN119403542A/zh active Pending
- 2023-04-28 JP JP2024563280A patent/JP2025515474A/ja active Pending
-
2024
- 2024-04-12 US US18/633,795 patent/US20240270864A1/en active Pending
- 2024-10-16 MX MX2024012785A patent/MX2024012785A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2563288T3 (es) | Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular | |
| RU2497516C2 (ru) | Композиция для местного введения | |
| CN1169525C (zh) | 紫杉烷的药物制剂 | |
| JP6259042B2 (ja) | タペンタドールを含む半固形の水性医薬組成物 | |
| US20100234462A1 (en) | Topical composition | |
| CN1128671A (zh) | 含环孢菌素的软胶囊组合物 | |
| GB2596184A (en) | Non-aqueous solutions for oral dosage | |
| CN106999440B (zh) | 含有紫杉烷的用于口服给药的药物组合物 | |
| JP7410883B2 (ja) | ワクチンアジュバントを含む製剤 | |
| AU2015270187A1 (en) | Oral pharmaceutical composition of isotretinoin | |
| JP2013541581A (ja) | タキソイドの医薬組成物 | |
| JP2022532965A5 (enExample) | ||
| RS54420B1 (sr) | Formulacija koja sadrži fenilaminopirimidinski derivat kao aktivni sastojak | |
| EP3849516A2 (en) | Non-aqueous chemotherapeutic suspensions for oral dosage | |
| WO2016071365A1 (en) | Topical pharmaceutical compositions of paclitaxel | |
| CA2701789A1 (fr) | Nouvelles compositions a base de taxoides | |
| RU2020130919A (ru) | Композиции и способы для лечения зуда | |
| JP2025529963A (ja) | カンナビジオールの新規非経口製剤 | |
| CN108136030B (zh) | 含有高浓度紫杉烷的用于口服给药的药物组合物 | |
| CN101890001B (zh) | 联苯双酯的药物组合物 | |
| WO2018182039A1 (ja) | 薬物を保持した非水系組成物およびその製造方法 | |
| HK40041450A (en) | Pharmaceutical composition for oral administration comprising taxane | |
| EP4568703A1 (en) | Stable injectable cannabidiol formulations | |
| KR101475110B1 (ko) | 허수테논 화합물의 안정화를 위한 제형 | |
| HK40041450B (en) | Pharmaceutical composition for oral administration comprising taxane |